Agalsidase alfa (Replagal^™) in the treatment of Anderson-Fabry disease

References

• AltarescuGHillSWiggsE2001The efficacy of enzyme replacement therapy in patients with chronic neuronopathic Gaucher’s diseaseJ Pediatr1385394711295718
   PubMed Web of Science ®Google Scholar
• BakerMPJonesTD2007Identification and removal of immunogenicity in therapeutic proteinsCurr Opin Drug Discov Devel1021927
   PubMed Web of Science ®Google Scholar
• BanikazemiMBultasJWaldekS2007Agalsidase-beta therapy for advanced Fabry disease: a randomized trialAnn Intern Med146778617179052
   PubMed Web of Science ®Google Scholar
• BarbeyFBrakchNLinhartA2006Cardiac and vascular hypertrophy in Fabry disease: evidence for a new mechanism independent of blood pressure and glycosphingolipid depositionArterioscler Thromb Vasc Biol268394416469946
   PubMed Web of Science ®Google Scholar
• BarbeyFBrakchNLinhartA2006Increased carotid intima-media thickness in the absence of atherosclerotic plaques in an adult population with Fabry diseaseActa Paediatr Suppl9563816720468
   PubMedGoogle Scholar
• BasiSLewisJB2006Microalbuminuria as a target to improve cardiovascular and renal outcomesAm J Kidney Dis479274616731288
   PubMed Web of Science ®Google Scholar
• BerthiaumeJTDavisJTairaDA2007A managed care organization’s use of integrated health management to improve secondary prevention of coronary artery diseaseAm J Manag Care13142717335357
   PubMed Web of Science ®Google Scholar
• BigazziRBianchiSNenciR1995Increased thickness of the carotid artery in patients with essential hypertension and microalbuminuriaJ Hum Hypertens9827338576899
   PubMed Web of Science ®Google Scholar
• BreunigFWeidemannFStrotmannJ2006Clinical benefit of enzyme replacement therapy in Fabry diseaseKidney Int6912162116609685
   PubMed Web of Science ®Google Scholar
• CaiSRXuGBecker-HapakM2006The kinetics and tissue distribution of protein transduction in miceEur J Pharm Sci273111916376528
   PubMed Web of Science ®Google Scholar
• CampeseVMParkJ2007HMG-CoA reductase inhibitors and the kidneyKidney Int7112152217495867
   PubMed Web of Science ®Google Scholar
• ClarkeJT2007Narrative review: Fabry diseaseAnn Intern Med1464253317371887
   PubMed Web of Science ®Google Scholar
• ClarkeJTRWestMLBultasJ2007Pharmacokinetics and pharmacodynamics of agalsidase alfa used for enzyme replacement therapy of Fabry diseaseGenetics in Medicine9504917700388
   PubMed Web of Science ®Google Scholar
• CloseLElliottP2007Optimization of concomitant medication in Fabry cardiomyopathyActa Paediatr Suppl9681317391449
   PubMedGoogle Scholar
• CoppoRD’AmicoG2005Factors predicting progression of IgA nephropathiesJ Nephrol185031216299675
   PubMed Web of Science ®Google Scholar
• EllederMBradovaVSmidF1990Cardiocyte storage and hypertrophy as a sole manifestation of Fabry’s disease. Report on a case simulating hypertrophic non-obstructive cardiomyopathyVirchows Arch A Pathol Anat Histopathol417449552173254
   PubMedGoogle Scholar
• ElliottPMKindlerHShahJS2006Coronary microvascular dysfunction in male patients with Anderson-Fabry disease and the effect of treatment with alpha galactosidase AHeart923576016085718
   PubMed Web of Science ®Google Scholar
• EngCMFletcherJWilcoxWR2007Fabry disease: baseline medical characteristics of a cohort of 1765 males and females in the Fabry RegistryJ Inherit Metab Dis301849217347915
   PubMed Web of Science ®Google Scholar
• EngCMGuffonNWilcoxWR2001Safety and efficacy of recombinant human alpha-galactosidase A-replacement therapy in Fabry’s diseaseN Engl J Med34591611439963
   PubMed Web of Science ®Google Scholar
• FerrariP2007Prescribing angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in chronic kidney diseaseNephrology (Carlton)1281917295666
   PubMed Web of Science ®Google Scholar
• GermainDPWaldekSBanikazemiM2007Sustained, long-term renal stabilization after 54 months of agalsidase Beta therapy in patients with fabry diseaseJ Am Soc Nephrol1815475717409312
   PubMed Web of Science ®Google Scholar
• GoldKFPastoresGMBottemanMF2002Quality of life of patients with Fabry diseaseQual Life Res113172712086117
   PubMed Web of Science ®Google Scholar
• GuptaSRiesMKotsopoulosS2005The relationship of vascular glycolipid storage to clinical manifestations of Fabry disease: a cross-sectional study of a large cohort of clinically affected heterozygous womenMedicine (Baltimore)84261816148726
   PubMed Web of Science ®Google Scholar
• HughesDAElliottPMShahJ2007Effects of enzyme replacement therapy on the cardiomyopathy of Anderson-Fabry disease: a randomized, double-blind, placebo-controlled clinical trial of agalsidase-alfaHeart54 [Epub ahead of print]
   Google Scholar
• IchinoseMNakayamaMOhashiT2005Significance of screening for Fabry disease among male dialysis patientsClin Exp Nephrol92283216189631
   PubMedGoogle Scholar
• ImbriacoMSpinelliLCuocoloA2007MRI characterization of myocardial tissue in patients with Fabry’s diseaseAJR Am J Roentgenol188850317312078
   PubMed Web of Science ®Google Scholar
• KikanoGEBrownMT2007Antiplatelet therapy for atherothrombotic disease: an update for the primary care physicianMayo Clin Proc825839817511957
   PubMed Web of Science ®Google Scholar
• LidoveOJolyDBarbeyF2007Clinical results of enzyme replacement therapy in Fabry disease: a comprehensive review of literatureInt J Clin Pract6129330217263716
   PubMed Web of Science ®Google Scholar
• LinthorstGEHollakCEDonker-KoopmanWE2004Enzyme therapy for Fabry disease: neutralizing antibodies toward agalsidase alpha and betaKidney Int6615899515458455
   PubMed Web of Science ®Google Scholar
• MacDermotKDHolmesAMinersAH2001aAnderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous malesJ Med Genet387506011694547
   PubMed Web of Science ®Google Scholar
• MacDermotKDHolmesAMinersAH2001bAnderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier femalesJ Med Genet387697511732485
   PubMed Web of Science ®Google Scholar
• MehtaARicciRWidmerU2004Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome SurveyEur J Clin Invest342364215025684
   PubMed Web of Science ®Google Scholar
• MooreDFGeldermanMPFerreiraPA2007Genomic abnormalities of the murine model of Fabry disease after disease-related perturbation, a systems biology approachProc Natl Acad Sci USA10480657017470787
   PubMed Web of Science ®Google Scholar
• MooreDFKaneskiCRAskariH2007The cerebral vasculopathy of Fabry diseaseJ Neurol Sci2572586317362993
   PubMed Web of Science ®Google Scholar
• MooreDFRiesMForgetEL2007Enzyme replacement therapy in orphan and ultra-orphan diseases: the limitations of standard economic metrics as exemplified by Fabry-Anderson diseasePharmacoeconomics25201817335306
   PubMed Web of Science ®Google Scholar
• MurrayGJAnverMRKennedyMA2007Cellular and tissue distribution of intravenously administered agalsidase alfaMol Genet Metab903071217188539
   PubMed Web of Science ®Google Scholar
• OwensCLRussellSDHalushkaMK2006Histologic and electron microscopy findings in myocardium of treated Fabry diseaseHum Pathol37764816733219
   PubMed Web of Science ®Google Scholar
• PastoresGM2003Enzyme therapy for the lysosomal storage disorders: principles, patents, practice and prospectsExpert Opin Ther Patents13115772
   Web of Science ®Google Scholar
• PastoresGM2004Agalsidase alfa (Replagal™): enzyme therapy for Anderson-Fabry diseaseTherapy120311
   Google Scholar
• PastoresGMBoydECrandallK2007Safety and pharmacokinetics of agalsidase alfa in patients with Fabry disease and end-stage renal diseaseNephrol Dial Transplant221920517395657
   PubMed Web of Science ®Google Scholar
• PastoresGMThadhaniR2002Advances in the management of Anderson-Fabry disease: enzyme replacement therapyExpert Opin Biol Ther23253311890871
   PubMed Web of Science ®Google Scholar
• RamaswamiUWendtSPintos-MorellG2007Enzyme replacement therapy with agalsidase alfa in children with Fabry diseaseActa Paediatr96122717187618
   PubMed Web of Science ®Google Scholar
• RiesMClarkeJTWhybraC2006Enzyme-replacement therapy with agalsidase alfa in children with Fabry diseasePediatrics1189243216950982
   PubMed Web of Science ®Google Scholar
• RolfsABottcherTZschiescheM2005Prevalence of Fabry disease in patients with cryptogenic stroke: a prospective studyLancet3661794616298216
   PubMed Web of Science ®Google Scholar
• SchellekensH2005Factors influencing the immunogenicity of therapeutic proteinsNephrol Dial Transplant20Suppl 6vi3915958824
   PubMed Web of Science ®Google Scholar
• SchiffmannRAskariHTimmonsM2007Weekly enzyme replacement therapy may slow decline of renal function in patients with Fabry disease who are on long-term biweekly dosingJ Am Soc Nephrol1815768317409308
   PubMed Web of Science ®Google Scholar
• SchiffmannRFloeterMKDambrosiaJM2003Enzyme replacement therapy improves peripheral nerve and sweat function in Fabry diseaseMuscle Nerve287031014639584
   PubMed Web of Science ®Google Scholar
• SchiffmannRKoppJBAustinHAI2001Enzyme replacement therapy in Fabry disease: a randomized controlled trialJAMA28527434911386930
   PubMed Web of Science ®Google Scholar
• SchiffmannRMurrayGJTrecoD2000Infusion of alpha-galactosidase A reduces tissue globotriaosylceramide storage in patients with Fabry diseaseProc Natl Acad Sci USA973657010618424
   PubMed Web of Science ®Google Scholar
• SchiffmannRRapkiewiczAAbu-AsabM2006Pathological findings in a patient with Fabry disease who died after 2.5 years of enzyme replacementVirchows Arch4483374316315019
   PubMed Web of Science ®Google Scholar
• SchiffmannRRiesMTimmonsM2006Long-term therapy with agalsidase alfa for Fabry disease: safety and effects on renal function in a home infusion settingNephrol Dial Transplant213455416204287
   PubMed Web of Science ®Google Scholar
• SessaAMeroniMBattiniG2004Chronic renal failure, dialysis, and renal transplantation in Anderson-Fabry diseaseSemin Nephrol24532615490423
   PubMed Web of Science ®Google Scholar
• ShahJSHughesDASachdevB2005Prevalence and clinical significance of cardiac arrhythmia in Anderson-Fabry diseaseAm J Cardiol96842616169374
   PubMed Web of Science ®Google Scholar
• ShahJSHughesDATayebjeeMH2007Extracellular matrix turnover and disease severity in Anderson-Fabry diseaseJ Inherit Metab Dis30889517160618
   PubMed Web of Science ®Google Scholar
• TanakaMOhashiTKobayashiM2005Identification of Fabry’s disease by the screening of alpha-galactosidase A activity in male and female hemodialysis patientsClin Nephrol64281716240899
   PubMed Web of Science ®Google Scholar
• VanceDEKrivitWSweeleyCC1975Metabolism of neutral glycosphingolipids in plasma of a normal human and a patient with Fabry’s diseaseJ Biol Chem250811925809441
   PubMed Web of Science ®Google Scholar
• van de WeertMJorgensenLHorn MoellerE2005Factors of importance for a successful delivery system for proteinsExpert Opin Drug Deliv210293716296807
   PubMedGoogle Scholar
• VedderACLinthorstGEHougeG2007Treatment of Fabry disease: outcome of a comparative trial with agalsidase alfa or beta at a dose of 0.2 mg/kgPLoS ONE2e59817622343
   PubMed Web of Science ®Google Scholar
• VedderACLinthorstGEvan BreemenMJ2007The Dutch Fabry cohort: diversity of clinical manifestations and Gb3 levelsJ Inherit Metab Dis30687817206462
   PubMed Web of Science ®Google Scholar
• WarnockDG2007Enzyme replacement therapy and Fabry kidney disease: quo vadisJ Am Soc Nephrol1813687017429046
   PubMed Web of Science ®Google Scholar
• WarnockDG2005Fabry disease: diagnosis and management, with emphasis on the renal manifestationsCurr Opin Nephrol Hypertens14879515687833
   PubMed Web of Science ®Google Scholar
• WhybraCSchwartingAKriegsmannJ2006IgA nephropathy in two adolescent sisters heterozygous for Fabry diseasePediatr Nephrol211251616838183
   PubMed Web of Science ®Google Scholar